COVERAGE HUB
$SNY
2 articles in last 30 days
LAST 30 DAYS
2 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
0
2-DAY GRADE TIMELINE
2026-06-12
TODAY
RECENT COVERAGE · 2 ARTICLES
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First (NASDAQ:SNY)
Sanofi (SNY) receives a bullish reassessment driven by accelerating commercialization momentum across two key therapeutic franchises....
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi's FDA approval of Tzield represents a significant clinical and commercial milestone in type 1 diabetes treatment. As the first...